PR Newswire (Wed, 4:21PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
43 people get AXN articles and Market Currents by email alert.
Get email alerts on AXN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
PR Newswire (Feb 15, 2013)
-
PR Newswire (Jan 28, 2013)
-
PR Newswire (Nov 14, 2012)
-
PR Newswire (Oct 15, 2012)
-
PR Newswire (Sep 13, 2012)
-
PR Newswire (Jul 6, 2012)
-
Marketwire (May 15, 2012)
-
Marketwire (Mar 22, 2012)
-
China Biotech Week In Review: Merck Plans Beijing R&D CenterChinaBio Today • Mon, Dec 12, 2011
-
PR Newswire (Dec 7, 2011)
-
China Biotech News: Eye on ShangPharma and AoxingChinaBio Today • Mon, Nov 29, 2010
-
Aoxing Moves Closer to Commercial Production of Narcotic DrugChinaBio Today • Tue, Nov 23, 2010
-
Aoxing Reports Progress in Narcotic API Manufacturing JVChinaBio Today • Wed, Oct 27, 2010
-
Aoxing Wins Approval for Trial of Drug Dependence TherapyChinaBio Today • Thu, Aug 26, 2010
-
China Biologic Products: Interview with VP FinanceZack Buckley • Tue, Jun 29, 2010
To learn more about Seeking Alpha Pro, click here.
-
China Biotech Week In Review: Merck Plans Beijing R&D CenterChinaBio Today • Mon, Dec 12, 2011
-
China Biotech News: Eye on ShangPharma and AoxingChinaBio Today • Mon, Nov 29, 2010
-
Aoxing Moves Closer to Commercial Production of Narcotic DrugChinaBio Today • Tue, Nov 23, 2010
-
China Biologic Products: Interview with VP FinanceZack Buckley • Tue, Jun 29, 2010
-
China Biotech Week in Review: CROs ConsolidatingChinaBio Today • Sun, May 2, 2010
There are no Transcripts on AXN.
-
PR Newswire (Wed, 4:21PM)
-
PR Newswire (Feb 15, 2013)
-
PR Newswire (Jan 28, 2013)
-
PR Newswire (Nov 14, 2012)
-
PR Newswire (Oct 15, 2012)
-
PR Newswire (Sep 13, 2012)
-
PR Newswire (Jul 6, 2012)
-
Marketwire (May 15, 2012)
-
Marketwire (Mar 22, 2012)
-
PR Newswire (Dec 7, 2011)
AXN vs. ETF Alternatives
Company Description
"China Aoxing Pharmaceutical (“China Aoxing” or the “Company”) is a specialty pharmaceutical company located in China specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, the... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, October 16, 2012, 3:36 PM Aoxing Pharmaceutical (AXN +7.4%) pops after the drug-maker reported a $15.9M net loss for FY12, but total revenue rose 22% year over year to $8.13M. The revenue gain was largely due to a 33% increase in sales of the company's main product, Zhongtongan, which is now being marketed for gynecological and orthopedic applications, in addition to its core dental market. Overall, Zhongtongan accounted for 89% of the company's FY12 sales. Comment! [Global & FX, Healthcare, Earnings, On the Move]
- Thursday, September 13, 2012, 3:31 PM Shares of Aoxing Pharmaceutical (AXN +17%) have shot up in afternoon trading on no particular news. The company declined comment, after being contacted by the NYSE Euronext in accordance with the usual practice. Comment! [Healthcare, On the Move]
-
Jim Van Meerten
AXN - China Aoxing Pharma - continues to rise 41.20% in a month - 96% Barchart technical buy signal - 17 new highs in the last 20 sessions - View all 0 replies
-
Jim Van Meerten
AXN - China Aoxing Pharma -13 new highs in 20 sessions - 100% Barchart buy signal - Wall Street strong buy recommendation on sales increases - View all 0 replies
LATEST REPLIES